Inside information, profit warning: Optomed receives a large order in the US and increases its full year outlook
Optomed Plc Inside Information 11 November 2024 at 21.00, Helsinki
Inside information, profit warning: Optomed receives a large order in the US and increases its full year outlook
Optomed has received a EUR 1.5 million order and increases its full year 2024 outlook.
The received order is from a US screening service provider. The order is traditional device capex transaction and does not include AI service or a recurring revenue component. The device stock levels for other products than Optomed Aurora AEYE are temporarily low after the delivery, and it may limit Optomed’s possibilities to make additional large capex deliveries in Q4-2024. Consequently, the Company now expects its full year 2024 revenue to stay on the same level as in 2023.
The updated outlook for 2024:
“Optomed expects its full year 2024 revenue to stay on the same level as in 2023.”
Previously outlook (announced 25 September 2024):
“Optomed expects its full year 2024 revenue to decrease from 2023.”
Optomed utilizes seven thresholds in relation to its revenue guidance: in Optomed’s outlook, the revenue may “grow/decrease very strongly”, “grow/decrease strongly”, “grow/decrease” or “stay on the same level”. The Company has set fixed internal percentages to reflect each threshold.
Optomed Plc
Further enquiries
Juho Himberg, CEO, [email protected]
Optomed in Brief
Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company’s products are sold via various sales channels in over 60 countries globally
